---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-000683"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:18:22.232987+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics amends bylaws to adopt universal proxy rules and update nomination procedures

## Summary
- Amended bylaws require compliance with SEC Rule 14a-19 for non-Board director nominee solicitations.
- Enhanced disclosure for stockholder nominations includes derivative interests and relationships with the Company.
- Stockholders may nominate no more director candidates than open board seats.
- Proxies solicited by stockholders must use a proxy card color other than white.
- Added personal jurisdiction and service-of-process clarifications for foreign actions under forum selection clause.

## SEC filing metadata
- accession: 0001193125-24-000683
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/0001193125-24-000683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/d582286d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-000683
- JSON: https://secwatch.observer/filing/0001193125-24-000683.json
- Plain text: https://secwatch.observer/filing/0001193125-24-000683.txt

## Key facts
- Governance Changes
  Seres Therapeutics, Inc.: Adopted Amended and Restated Bylaws with changes to proxy rules, stockholder nominations, and technical updates (effective 2024-01-02).
  - Change: bylaw amendment
  - Effective: 2024-01-02
  source text: On January 2, 2024, the Board of Directors (the “ Board ”) of Seres Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted the Company’s Amended and Restated Bylaws (the “ Amended and Restated Bylaws ”), which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524000683/0001193125-24-000683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.